End of an era for erythropoiesis‐stimulating agents in oncology. Issue 10 (28th February 2020)

• Record Type: Journal Article
• Authors: Schoen, Martin W.; Hoque, Shamia; Witherspoon, Bartlett J.; Schooley, Benjamin; Sartor, Oliver; Yang, Y. Tony; Yarnold, Paul R.; Knopf, Kevin B.; Hrushesky, William J.M.; Dickson, Michael; Chen, Brian J.; Nabhan, Chadi; Bennett, Charles L.
• Is Part Of: International journal of cancer. Volume 146:Issue 10(2020)
• Page Start: 2829
• Page End: 2835
• Publication Date: 2020-02-28
• Subjects: erythropoeitin -- oncology -- deimplementation -- adverse events -- erythropoesis‐stimulating agents; Cancer -- Periodicals; Cancer -- Prevention -- Periodicals; 616.994
• DOI: 10.1002/ijc.32917
• Languages: English
• ISSNs: 0020-7136

Abstract

Abstract : Erythropoiesis‐stimulating agents (ESAs) are available to treat chemotherapy‐induced anemia (CIA). In 2007–2008, regulatory notifications advised of venous thromboembolism and mortality risks while the Center for Medicare and Medicaid Services' restricted ESA initiation to patients with hemoglobin <10 g/dl. In 2010, a Risk Evaluation and Mitigation Strategies required consent prior to administration. We evaluated ESA utilization from 2003 to 2012 and obtained private health insurer claims data for persons with lung, colorectal, or breast cancer from 2001 to 2012. ESA use for CIA was determined by an ESA claim after chemotherapy, up to 6 months after treatment. We identified 839, 948 commercially insured patients, including 24, 785 patients with ESA‐treated CIA (3.2%). Darbepoetin use increased 3.9‐fold from 2003 to 2007 (12.3% to 48.7%) and then decreased 95% to 2.6% by 2012. Epoetin use decreased 90% from 2003 to 2012 (30.3% to 3.1%). Between 2003 and 2012, mean epoetin dosing decreased 0.8‐fold (244, 979 in 2003 vs. 196, 216 units in 2012), but increased 1.8‐fold for darbepoetin‐treated CIA (262 in 2003 to 467 μg in 2012). Among CIA patients, transfusions were low (4.5%) in 2002–2007, then increased 2.2‐fold between 2008 and 2012. Safety initiatives between 2007 and 2010 facilitated reductions in ESA use combined with changes in coverage. These data show the efficacy of regulatory efforts, publication of adverse events and changes in reimbursement in reducing use of ESAs. Future studies are warranted to optimize deimplementation strategies to improve patient safety. What's new?: Chemotherapy‐induced anemia was theorized to impair quality of life, and delay administration of chemotherapy, but is potentially overcome with erythropoiesis‐stimulating agents (ESAs). The safety and effectiveness of ESAs, however, came into question in the early 2000s. The extent of their current use is now minimal in the United States. In the present analysis, ESA prescribing was found to have dropped significantly after 2004, when safety concerns were first raised. Prescribing further declined following changes in reimbursement introduced in 2008 by the U.S. Center for Medicare and Medicaid Services. The changes in ESA prescribing may be used to inform de‐implementation processes for other pharmaceuticals with known harms.